Results of a Phase 2 Clinical Trial Using Technology Developed at Northwestern Medicine for the Treatment of Celiac Disease Look Promising!
“Results of a new phase 2 clinical trial using technology developed at Northwestern Medicine show it is possible to induce immune tolerance to gluten in individuals with celiac disease. The findings may pave the way for treated celiac patients to eventually tolerate gluten in their diet.
After treatment with the technology, the patients were able to eat gluten with a substantial reduction in inflammation. The results also show a trend toward protecting patients’ small intestine from gluten exposure.
The findings will be presented as a late-breaking presentation Oct. 22 at the European Gastroenterology Week conference in Barcelona, Spain.”
Read more here
Celiac disease expert, Dr. Alessio Fasano, weighs in on this study, open here (Youtube Video)
